Stocktoria

PMV Pharmaceuticals, Inc. PMVP

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-09-25

PMV Pharmaceuticals, Inc. financials (annual)

Revenue
2019202020212022202320242025
Net income
-$25.4M -$34.4M -$57.8M -$73.3M -$69.0M -$58.7M -$77.7M 2019202020212022202320242025
Free cash flow
-$22.2M -$32.9M -$47.9M -$71.7M -$56.6M -$51.9M -$73.6M 2019202020212022202320242025

Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019
R&D expense$69.9M$58.5M$55.9M$52.0M$36.5M$23.9M$20.8M
Operating income-$86.2M-$85.4M-$80.1M-$77.0M-$58.3M-$34.9M-$26.6M
Income tax-$2.2M-$16.1M$2,000-$9,000$23,000$6,000$8,000
Net income-$77.7M-$58.7M-$69.0M-$73.3M-$57.8M-$34.4M-$25.4M
EPS (diluted)$-1.48$-1.14$-1.44$-1.61$-1.28$-2.40
Operating cash flow-$73.6M-$51.3M-$55.7M-$63.8M-$46.6M-$32.7M-$22.1M
Free cash flow-$73.6M-$51.9M-$56.6M-$71.7M-$47.9M-$32.9M-$22.2M
Cash & equivalents$38.0M$40.9M$37.7M$108.3M$172.5M$361.4M$73.3M
Total assets$116.6M$191.3M$252.2M$270.3M$331.6M$365.5M$103.0M
Total liabilities$11.8M$15.2M$26.5M$24.3M$23.0M$6.4M$4.6M
Shareholders' equity$104.7M$176.1M$225.7M$246.0M$308.6M$359.1M-$70.5M

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.